Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 12406
Sealed predictions
- SRGN in dopamine neurons, braak+0.73 (p 0.026) → -0.48 (p 0.192)receipt 12414
Swarm cases
receipt 12414: SRGN in dopamine neurons, braak
- power
- full sample -0.05 (p 0.840, n 18), 95% CI -0.51 to +0.43. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.07 (p 0.774, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.05 (p 0.834, n 18). could be the mix.
- skeptic
- leave-one-out range -0.18 to +0.09, sign flips 3; without severely affected donors -0.05 (p 0.840, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SRGN in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts